Article information
Full text is only aviable in PDF
Bibliografía
[1.]
S. Benchimol, A. Fuks, S. Jothy, N. Beauchemin, K. Shirota, C. Stanners.
Carcinoembrionic antigen, a human tumor marker, functions as an intercellular adhesión molecule.
Cell, 57 (1989), pp. 327-334
[2.]
A.J. Vangsted.
Serological tumor markers for small cell lung cancer and their therapeutic implications.
APMIS, 102 (1994), pp. 561-580
[3.]
P. Santabárbara.
Marcadores tumorales en el cáncer broncopulmonar.
Arch Bronconeumol, 24 (1988), pp. 107-109
[4.]
J. Järvisalo, M. Hakama, P. Knekt, U.H. Stenman, A. Leino, L. Teppo, et al.
Serum tumor markers CEA, CA 50. TATI and NSE in lung cancer screening..
Cancer, 71 (1993), pp. 1.982-1.983
[5.]
W. Ebert, T.H. Muley, P. Drings.
Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?.
Anticancer Res, 16 (1996), pp. 2.161-2.168
[6.]
P.W. Brandt-Rauf, J.C. Luo, W.P. Carney, S. Smith, I. DeVivo, C. Mining, et al.
Detection of increased amounts of the extracellular domain of the C-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans.
Int J Cáncer, 56 (1994), pp. 383-386
[7.]
R. Lubin, G. Zalcman, L. Bouchet, J. Trédaniel, Y. Legros, D. Cazals, et al.
Serum p53 antibodies as early markers of lung cancer.
Nature Medicine, 1 (1995), pp. 701-702
[8.]
R. Partanen, H. Koskinen, K. Hemminki.
Tumor necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer.
Occup Environ Med, 52 (1995), pp. 316-331
[9.]
J.E. Boers, G.P.M. Ten Velde, B.J.M. Thunnissen.
P53 in squamous metaplasia: a marker for risk fo respiratory tract carcinoma.
Am J Respir Crit Care Med, 153 (1996), pp. 411-416
[10.]
J.R. Hernández Hernández.
Genética y cáncer de pulmón.
Actualizaciones SEPAR. Volumen 2, pp. 71-96
[11.]
J.M. Pinkham, R.C. Strange, C. Pantin.
Examination of bronchoalveolar wash fluid for ras, myc, and fos oncoproteins and glutathione Stransferase isoenzymes: an attempt to improve the accuracy of lung cancer diagnosis.
Clin Chim Acta, 227 (1994), pp. 211-215
[12.]
L. Mao, R.H. Hruban, J.O. Boyle, M. Tockman, D. Sidransky.
Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.
Cancer Res, (1994), pp. 1.634-1.637
[13.]
J.R. Hernández Hernández, J.A. Tapias, M.A. Garcinuño, J.M. Barragán, A. Gómez, E. Navarro, et al.
Marcadores tumorales en el carcinoma broncogénico. Utilidad diagnóstica y relación con la extensión neoplásica.
Arch Bronconeumol, 32 (1996), pp. 63
[14.]
J.L. Pujol, J. Grenier, E. Parrat, M. Lehmann, T. Lafontaine, X. Quantin, et al.
Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21.1 and TPS.
Am J Respir Crit Care Med, 154 (1996), pp. 725-733
[15.]
W. Ebert, H. Dienemann, A. Fateh-Moghadam, M. Scheulen, N. Konietzko, T. Schleich, et al.
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembrionic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer.
Eur J Clin Chem Clin Biochem, 32 (1994), pp. 189-199
[16.]
D. Rastel, A. Ramaioli, F. Comillie, B. Thirion.
CYFRA 21-1, a sensitive and specific new tumor marker for squamous cell lung cancer. Report of the First european multicentre evaluation.
Eur J Cancer, 30 (1994), pp. 601-606
[17.]
A. Pastor, R. Menéndez, M.J. Cremades, V. Pastor, R. Llopis, J. Aznar.
Diagnostic value of SCC. CEA and CYFRA 21.1 in lung cancer; a bayesian analysis.
Eur Respir J, 10 (1997), pp. 603-609
[18.]
M.S. Huang, S.B. Jong, M.S. Tsai, M.S. Lin, I.W. Chong, H.C. Lin, et al.
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumor markers in bronchogenic carcinoma.
Respir Med, 91 (1997), pp. 135-142
[19.]
V. Villena, A. López-Encuentra, J. Echave-Sustaeta, P. Martín-Escribano, B. Ortuño-de-Solo, J. Estenoz-Alfaro.
Diagnostic value of CA 72-4, carcinoembrionyc antigen, CA 15-3, and CA 19-9 assay in pleural fluid.
Cancer, 78 (1996), pp. 736-740
[20.]
J.R. Hernández Hernández, J.M. García García, M.A. Martínez Muñiz, M.T. Allende Monclus, A. Ruibal Morell.
Clinical utility of hyaluronic acid values in serum and bronchoalveolar lavage fluid as tumor marker for bronchogenic carcinoma.
Int J Biol Markers, 10 (1995), pp. 149-155
[21.]
L. Trevisani, S. Putinati, S. Sartori, V. Abbasciano, B. Bagni.
Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Chest, 109 (1996), pp. 104-108
[22.]
R. Rami Porta, J.L. Duque Medina, J.R. Hernández Hernández, A. López Encuentra, J. Sánchez de Cos Escuín.
Diagnóstico y estadificación del carcinoma broncogénico.
Recomendaciones SEPAR N. ° 21, Doyma, (1996),
[23.]
G. Buccheri, D. Ferrigno.
The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer.
Chest, 107 (1995), pp. 471-476
[24.]
G. Buccheri, A. Biggi, D. Ferrigno, M. Quaranta, A. Leone, G. Vassallo, et al.
Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer.
Thorax, 51 (1996), pp. 359-363
[25.]
B. Passlick, J.R. Izbizki, B. Kuboschok, W. Nathrath, O. Thetter, U. Pichlmeier, et al.
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer.
J Clin Oncol, 12 (1994), pp. 1.827-1.832
[26.]
K. Pantel, J. Izbicki, B. Passlick, M. Angstwurn, K. Håussinger, O. Thetter, et al.
Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases.
Lancet, 347 (1996), pp. 649-653
[27.]
M. Díez, A. Gómez, F. Hernando, M.D. Ortega, M.L. Maestro, A. Torres, et al.
Serum CEA, CA 125, and SCC antigens and tumor recurrence in resectable non-small cell lung cáncer..
Int J Biol Markers, 10 (1995), pp. 5-10
[28.]
J. Niklinsky, M. Furman, M. Rapellino, L. Chyczewski, J. Laudanski, A. Oliaro, et al.
CYFRA 21-1 determination in patients with nonsmall cell lung cancer: clinical utility for the detection of recurrences.
J Cardiovasc Surg, 36 (1995), pp. 501-504
[29.]
B.E. Johnson, D.C. Ihde, R.W. Macuch, A.F. Gazdar, D.N. Camey, H. Oie, et al.
Myc family oncogene amplification in tumor cells lines stablished from small cell lung cancer patients and its relationship to clinical status and course.
J Clin Invest, 79 (1987), pp. 1.629-1.634
[30.]
G. Buccheri, D. Ferrigno.
Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and postreatment disease status.
Lung Cancer, 13 (1995), pp. 155-168
[31.]
A. Spinazzi, E. Soresi, R. Boffi, A. Nonis, A. Noseda, S. Cobelli, et al.
Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Cancer Detection and Prevention, 18 (1994), pp. 209-220
[32.]
J.T. Schleusener, H.D. Tazelaar, S. Jung, S.S. Cha, P.J. Cera, J.L. Myers, et al.
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Cancer, 77 (1996), pp. 1.284-1.291
[33.]
J.L. Pujol, E.H. Cooper, M. Lehmann, D.A. Purves, M. Dan-Aouta, J. Midander, et al.
Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
Br J Cancer, 67 (1993), pp. 1.423-1.429
[34.]
L.G.M. Jorgensen, K. Osterlind, J. Genollá, S.A. Gomm, J.R. Hernández, P.W.M. Johnson, et al.
Serum neuron-specific enolase and the prognosis in small-cell lung cáncer: a combined multivariable analysis on data from nine centres.
Br J Cancer, 74 (1996), pp. 463-467
[35.]
G. Jaques, B. Auerbach, M. Pritsch, M. Wolf, N. Madry, K. Havemann.
Evaluation of serum neural cell lung cancer.
Cancer, 72 (1993), pp. 418-425
[36.]
G. Buccheri, D. Ferrigno, F. Vola.
Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer.
Lung Cancer, 10 (1993), pp. 21-33
[37.]
B. Wieskopf, C. Demangeat, A. Purohit, R. Stenger, P. Gries, H. Kreisman, et al.
CYFRA 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity and prognostic role.
Chest, 108 (1995), pp. 163-169
[38.]
M. Díez, A. Torres, M.L. Maestro, M.D. Ortega, A. Gómez, M. Pollán, et al.
Prediction of survival and recurrence by serum and cytosolic levels of CEA. CA 125 and SCC antigens in resectable non-smallcell lung cancer.
Br J Cancer, 73 (1996), pp. 1.248-1.254
[39.]
J.S. Lee, J.I. Ro, A.A. Sahin, W.K. Hong, B.W. Brown, C.F. Mountain, et al.
Expression of blood group antigen A. A favorable prognostic factor in non small cell lung cancer.
N Engl J Med, 324 (1991), pp. 1.084-1.090
[40.]
H. Matsumoto, H. Muramatsu, T. Shimotakahara, M. Yanagi, H. Nishijima, N. Mitani, et al.
Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas.
Cancer, 72 (1993), pp. 75-81
[41.]
M. Miyake, T. Thoshihiko, S. Hitomi, S. Hakomori.
Correlation of expression of H/Ley/Leb Antigens with survival in patients with carcinoma of the lung.
N Engl J Med, 327 (1992), pp. 14-18
[42.]
R.J.C. Slebos, R.E. Kibbelaar, O. Dalesio, A. Kooistra, J. Stam, C.J.L.M. Meijer, et al.
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
N Engl J Med, 323 (1990), pp. 561-565
[43.]
R. Rosell, S. Li, Z. Skacel, J.L. Mate, J. Maestre, M. Canela, et al.
Prognostic impact of mutated K-ras gene in surgically resecteds non-small cell lung cancer patients.
Oncongene, 8 (1993), pp. 2.407-2.412
Copyright © 1997. Sociedad Española de Neumología y Cirugía Torácica
